Objectives To confi rm the effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab in patients with rheumatoid arthritis (RA) in a setting close to real-life medical care in Germany.
INTRODUCTION
During the past years the treatment of rheumatoid arthritis (RA) has changed considerably. 1 2 In addition to treatment with conventional diseasemodifying antirheumatic drugs (DMARDs), biological agents have emerged with the capability of specifi cally targeting single components within the infl ammatory cascade 3 such as inhibiting tumour necrosis factor (TNF) α 4 or interleukin (IL)-1, 5 targeting CD20 B cells 6 or interfering with T cell activation by blocking CD80/86:CD28 signalling. 7 However, approximately 70% of patients still fail to achieve remission and approximately 29-54% do not show signifi cant improvement with TNFα antagonists. 8 -10 The development of other innovative targeted therapies with alternative modes of action is therefore needed.
Tocilizumab, a recombinant humanised monoclonal IgG 1 antihuman interleukin 6-receptor antibody represents such a new treatment option in patients with moderate to severe active RA who have either responded inadequately or were intolerant to previous treatment with one or more DMARDs or TNF antagonists.
In clinical studies it was shown that tocilizumab is well tolerated and effi cacious in alleviating the signs and symptoms of RA, 11 -15 as well as inhibiting radiological progression. 16 17 The results of these studies led to its approval by the European Medicines Agency (EMA) in January 2009 and by the FDA in January 2010. The clinical phase II and III studies, however, required strict eligibility criteria and rigid adherence to a comprehensive schedule of studyrelated events. In the phase IIIb study (TAMARA), the effi cacy and safety of tocilizumab in a setting closer to daily practice was investigated. consisting of 24.5% men and 75.5% women aged 18-84 years. All but one patient was pretreated with DMARDs, mostly with methotrexate (95.1%) or lefl unomide (60.1%), and 41.6% of patients were pretreated with TNFα antagonists. During the study, concomitant methotrexate was used by 72.0%, lefl unomide by 19.6%, glucocorticoids by 70.6% and nine patients received tocilizumab monotherapy (see fi gure 3 in the online supplement). Deviations from the protocol leading to exclusion from the per protocol population (PP) occurred in 153 patients (deviations with a frequency of >5% are listed in fi gure in the online supplement), but only 11 patients (3.3%) had to be withdrawn because of protocol violations. Thus, 133 patients were valid for inclusion in the strict PP population. Overall, the protocol deviations had no League Against Rheumatism (EULAR) response, DAS remission, American College of Rheumatology (ACR) responses and the safety of tocilizumab with regard to adverse events (AEs), laboratory assessments and physical examination. In addition, effects on health-related quality of life outcomes in the study population were assessed. Details of the study population, statistics and methods are shown in the online supplement.
METHODS

Study design and patients
TAMARA ( T ocilizumab A nd D M ARDs: A chievements in R heumatoid A rthritis),
RESULTS Patients
After screening of 334 patients, 286 patients were enrolled in the study and 85.6% completed the 24-week period and were included in the primary analysis intention-to-treat (ITT) population response, DAS remission in 48.2%, LDAS in 57.1%) which was comparable to the results observed in the entire cohort. The signifi cant results obtained with the DAS28 assessments were confi rmed by improvements in all other secondary effi cacy parameters. As shown in fi gure 2A, the self-reported 'patient take home form' indicated that the strongest effects had already appeared within the fi rst 4 weeks of treatment (ie, following the very fi rst infusion) in pain, morning stiffness and fatigue. Also, in other patientreported outcomes, improvement in health-related quality of life measured by the Health Assessment Questionnaire-Disease Index (HAQ-DI) was reported ( fi gure 2B ), and also in the Short Form-36 (SF-36) which showed an improvement in physical functioning and vitality as well as in social functioning and mental health.
The mean global satisfaction of patients with the treatment according to the Treatment Satisfaction Questionnaire for Medication was 74.7±25.9%. At week 24, 72.8% of patients in the DMARD-IR subgroup and 65.5% of patients in the TNF antagonist-IR subgroup were satisfi ed with the effectiveness of the treatment and 89.7% in the DMARD-IR subgroup and 88.5% in the TNF antagonist-IR subgroup were satisfi ed with the tolerability. Global satisfaction with the medication was reported by 77.8% of patients in the DMARD-IR subgroup and 71.6% of patients in the TNF antagonist-IR subgroup.
Safety
The safety profi le of tocilizumab was comparable to that previously observed. A total of 242 patients (84.6%) experienced at least one AE during the study. Most of the AEs were mild or moderate and resolved by the end of the study. No deaths were reported. Sixteen patients (5.6%) were withdrawn from treatment due to AEs and 10 (3.5%) due to study drug-related AEs. Table 3 in the online supplement shows the most common study drug-related AEs and differences in the incidence of AEs between patients pretreated with DMARDs or TNF antagonists.
Fifteen patients (5.2%) had serious AEs related to the study drug, which were mostly infections. In nine patients with infections (3.1%) at least one infection was serious (see table 3 in online supplement for details). Three patients prematurely discontinued the study due to serious infections. No serious AEs related to the study drug occurred at frequencies ≥1%.
AEs of special interest occurred in 156 patients (54.5%) and in 120 (42.0%) at least one was rated as drug-related. The highest incidence rates were seen in lipid elevations (29.7% in total; 23.4% drug-related) and infections (28.7% in total; 17.8% drugrelated). The mean changes in the lipid panel (total cholesterol, triglycerides, high-density lipoprotein and low-density lipoprotein) indicated mild increases and only in a few patients (n=15) detectable infl uence on the study outcomes; the results of the ITT and PP populations were nearly identical.
Effi cacy
Analysis of the primary effi cacy variable showed that 163 of the 286 patients (57.0%) in the ITT population achieved a Low Disease Activity Score (LDAS) at week 24 (63.2% with DMARD pretreatment and 50.4% with TNF antagonist pretreatment). More DMARD-IR patients (53.4%) than TNF antagonist-IR patients (41.2%) reached DAS remission ( fi gure 1A ).
Tocilizumab showed a very early onset of action. The mean DAS28 at baseline was 6.0±1.0 points. After the fi rst infusion the mean DAS28 decreased by 21.5±18.0% within 1 week and by 40.1±19.9% within 4 weeks. 75.2% of patients experienced a clinically signifi cant reduction by ≥1.2 DAS28 points, 40.9% achieved an LDAS and 23.1% were in DAS28 remission after only one infusion. Thereafter, mean disease activity continuously decreased: by week 24 mean DAS28 decreased from 6.0±1.0 points at baseline to 2.6±1.5 points (reduction of 56.8±22.5%).
Most of the patients had a high disease activity at baseline; 79.2% had a DAS28 >5.1 which decreased by 16.1% at week 4, and only 6.6% persistently had a DAS >5.1 at week 24 while most (53.0%) of the patients achieved LDAS and 44% were in DAS28 remission. Of the patients with a baseline DAS28 between >3.2 and ≤5.1 (n=54), 74% achieved LDAS and 61% achieved DAS28 remission at week 24 ( fi gure 1B ).
ACR response rates at week 24 showed that 65.0% of the patients met the criteria for an ACR20 response, 50.7% for an ACR50 response and 33.9% for an ACR70 response. These improvements were seen in all components of the ACR core set, notably in the number of swollen and tender joints which signifi cantly decreased in both DMARD-IR and TNF antagonist-IR patients ( table 1 ) . After 24 weeks, 33% of patients had a tender joint count (TJC) of 0 and 42% had a swollen joint count (SJC) of 0; 26% of patients had both TJC and SJC of 0 ( fi gure 1C ). Accordingly, the Clinical Disease Activity Index decreased by 70.9±29.3% from 34.7±12.5 to 11.3±11.5 within 24 weeks.
A subgroup analysis of RF-positive versus RF-negative patients did not show a statistically signifi cant difference in DAS28, EULAR or ACR responses at week 24 ( table 2 ), although RF-positive patients had a higher DAS28 than RF-negative patients at baseline (6.1 vs 5.7). Moreover, age, sex, body mass index, concomitant diseases and pretreatment did not differ between the two groups (data not shown). In addition, the subgroup of patients with concomitant lefl unomide therapy achieved a signifi cant clinical improvement (55.4% EULAR good had failed with a TNF antagonist. Concomitant DMARD therapy was continued, which was most often methotrexate (72.0%) but 19.6% of the patients were treated with lefl unomide, refl ecting the 'real-life' scenario. The high number of protocol deviations also refl ects a 'real-life' scenario, but only a few patients had to be withdrawn from the study. Protocol violations did not infl uence study outcome parameters as the results of the ITT and PP populations were virtually identical. The TAMARA study confi rmed the good effi cacy observed in different patient populations in previous studies (see table 4 in the online supplement). 11 -13 15 16 Treatment showed a very early onset of action as the mean DAS28 decreased by 40±20% after the fi rst tocilizumab infusion. At week 24, 57% of the patients had achieved the primary end point of LDAS and 47.6% even achieved DAS remission. Remarkably, 79.2% of the patients in our study had high RA activity with a DAS28 >5.1 at baseline. Of important clinical relevance is the fact that tocilizumab treatment was particularly benefi cial in these patients, 42% of whom achieved DAS28 remission by week 24. Furthermore, the quality of life as refl ected by the HAQ-DI, SF-36 and fatigue score also improved. In all, 75% of the patients reported an overall satisfaction with the treatment.
Because of the strong effect of tocilizumab on the acute phase reactants (APR), it is a matter of debate whether the high remission rates resulting from tocilizumab are mainly driven by the reduction in APR . This can be rebutted by the strong decrease in the number of swollen and tender joints as well as the high percentage of patients (26%) with no TJC and no SJC ( fi gure 1 ).
were the individual changes clinically signifi cant at the last assessment. Raised aminotransferases were reported in 7.3% of patients (5.6% drug-related) and low neutrophil counts in 2.4% (all drug-related).
DISCUSSION
TAMARA was the fi rst phase IIIb study preceding the approval of tocilizumab in January 2009 to be performed in a setting close to real-life medical care and confi rmed the rapid and sustained improvement in signs and symptoms of RA with tocilizumab as well as a manageable safety profi le.
The TAMARA study was conducted in 286 patients with active RA who had received 1-4 previous DMARDs; in 41.6% treatment Subgroup analyses revealed a comparable clinical response in RF-positive and RF-negative patients that has not been reported previously. Patients with concomitant lefl unomide treatment did not differ from the whole cohort with regard to effi cacy parameters and safety, indicating that lefl unomide may represent a suitable concomitant DMARD.
Not unexpectedly, patients who had failed with previous DMARDs showed a better clinical response than patients who had shown an inadequate response to previous TNF antagonists, possibly because of their longer disease duration, the earlier use of tocilizumab or because they may have had a less refractory form of RA.
The treatment with tocilizumab was well tolerated. The incidence rates of all AEs (83.9%) and of drug-related AEs (66.1%) as well as the incidence of serious infections were as expected from the published reports. Most of the AEs were mild or moderate and resolved by the end of the study. The only unexpected serious AE in this study was a relapse of a pre-existing but previously undiagnosed case of multiple sclerosis (MS) which was rated as drugrelated. This patient had a history of several neurological disorders (including unspecifi ed foci on the MRI), but the diagnosis of MS was not established before the study. Reassessment of the medical charts, however, confi rmed the pre-existence of a relapsing-remitting MS and the serious AE was changed to 'MS-relapse'. Thus, a causal relationship with tocilizumab could not be excluded.
This study was performed in a setting close to real-life medical care; however the non-controlled design and the short observation period of 24 weeks provide only limited data with respect to long-term effi cacy and potential safety issues. Nevertheless, studies close to real-life medical care in usual clinical practice in a heterogeneous patient population have a high degree of relevance as results of controlled studies do not always match with daily medical care. Only 21-33% of patients in the German RABBIT register treated with biological agents would have been eligible for the major trials with TNFα antagonists. In the clinical setting, the indications for treatment with biological agents were not identical to the inclusion criteria for trials, and there was a smaller relative improvement achieved in the patients with RA who would not have fulfi lled the inclusion criteria of the trials. 18 Interestingly, the heterogeneous patient population from the TAMARA study showed even better effi cacy results than patients from previously published controlled studies (see table 4 in the online supplement). We therefore believe that these data confi rm that tocilizumab represents an important treatment option for patients with RA in a real-life setting.
CONCLUSIONS
This study demonstrated the effi cacy of tocilizumab in combination with a traditional DMARD in a heterogeneous patient population with moderate to severe active RA. The good efficacy of tocilizumab was accompanied by a manageable safety profi le, which was in accordance with the safety data obtained during the clinical development programme of tocilizumab.
